Two Yipinhong Drugs Tentatively Selected for the 12th National Centralized Drug Procurement

财中社··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Yipinhong announced that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical's isavuconazonium sulfate for injection and Guangzhou Lianrui Pharmaceutical's perindopril amlodipine tablets (III) have been tentatively selected for the 12th National Centralized Drug Procurement. Isavuconazonium sulfate for injection had sales revenue of zero yuan in 2025, while perindopril amlodipine tablets (III) achieved sales revenue of 3.4817 million yuan, accounting for 0.37% of the company's 2025 operating revenue. In the first quarter of 2026, Yipinhong recorded revenue of 385 million yuan and net profit attributable to the parent of 594 million yuan.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 1

Guangzhou Lianrui Pharmaceutical Co., Ltd.Private▲ Positive
Demandrelevance

Perindopril amlodipine tablets selected, though current revenue contribution is minimal.

© 2026 MarketIVNews